TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: canal cleanliness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 12-month all-cause hospitalization risk
Endpoint domain: Mortality/survival
Primary endpoint: 12-month CD-related hospitalization risk
Endpoint domain: Mortality/survival
Primary endpoint: CD-related surgeries
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: state anxiety reduction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: SigmaST levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of uncovered struts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Rates of strut malapposition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Discontinuities in BVS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: occluded dentin orifices
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for hospitalization
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Adherence to vaccination recommendations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rise in quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Sensitivity for cartilaginous defects
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection rate for subchondral bone marrow signal abnormality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interobserver agreement for evaluation of intraarticular structures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fundamental movement skill difficulties
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical abilities self‐concept
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Fusion rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Defervescence within 72 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Response rate at 21 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Mean total antibiotic drug cost
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: submaximal VO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Respiratory tract infections (RTIs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of patients achieving target HbA1c
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Symptomatic hypoglycemia events per patient-year
Endpoint domain: Adverse events/effects
Primary endpoint: Mesor of D-dimer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Amplitude of D-dimer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mesor of plasminogen activator inhibitor-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Single-leg squat mechanics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Use of alcohol and cigarettes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Use of marijuana
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: psychometric performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hp eradication rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ulcer recovery rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence rate of Hp infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correct identification of yeasts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adjusted mean BCVA change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median time to first implant refill
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Postoperative vitreous hemorrhage rate
Endpoint domain: Adverse events/effects
Primary endpoint: air pollution preventive behaviors
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: angular displacement in response to perturbation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: marked or moderate benefit
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: seizure rate
Endpoint domain: Adverse events/effects
Primary endpoint: Development of significant anemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Improvement in passive dorsiflexion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Improvement in walking endurance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in Physician Rating Scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in LV end-diastolic volume (ΔLVEDV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: peritonitis episodes
Endpoint domain: Adverse events/effects
Primary endpoint: exit site infections (ESIs)
Endpoint domain: Adverse events/effects
Primary endpoint: time to first event
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of orbital radiotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Staining scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: adherence to dietary changes
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: weight loss at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: weight loss at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in VAS pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients experiencing pain relief within 1-10 inhalations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: global relief of IBS symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Hostility ratings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Creatine kinase levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: major postoperative thromboembolism
Endpoint domain: Mortality/survival
Primary endpoint: diffuse bleeding complication
Endpoint domain: Adverse events/effects
Primary endpoint: Need for more pressure to obtain a bloodless surgical field
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Incidence of skin complications at the tourniquet application site
Endpoint domain: Adverse events/effects
Primary endpoint: Symptoms related with rotator cuff disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vastus medialis obliquus amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Parasite clearance duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parasitological cure rate on day 14
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical activity levels (steps)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Modification in global EEG spectral power
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: postoperative sensitivity to cold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean deviation of visual field testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Pattern standard deviation of visual field testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Visual functioning quality of life (VS-QOL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Cure or long-term remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in symptomatology on the HAM-D
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Global Impression (CGI) total scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Remission rates on the HAM-D
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: P(0.1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: V(E)/P(0.1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Oxygenation levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Subjective sensations of dyspnea
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion of patients achieving targeted BP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: cure or improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Worsening of positive symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Renal Mg clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Reduction in risky sexual behaviors
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: quadriceps pain
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: serum concentration of TNF-α
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Prevalence of falls
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of neuropsychometric deficit
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Middle cerebral artery velocity (MCAV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Jugular bulb pO2 change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Q-Tc interval changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Probability of vaginal birth after cesarean section
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Cervical dilatation at the moment of hospitalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: serum CXCL10 concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Postoperative parathyroid malfunction rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: inhibitory failures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: response times
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: self-reported stimulation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: functional respiratory capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: inspiratory capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Signs of pulmonary embolism (PE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incontinence Improvement (IEF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of Life Improvement (I-QOL score)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Voiding Interval Increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hair cortisol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Success rate of placement on the first attempt
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stabilisation of positive symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Excellent 2-year outcomes
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: maternal outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Isobaric compliance of the brachial artery decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Temporal artery diameter decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Hip function measured by HHS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mobility measured by TUG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major reoperations
Endpoint domain: Adverse events/effects
Primary endpoint: Perceived level of energy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Diurnal IOP reductions of 30% or more from baseline to week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Height outcome (HT-SDS change)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: jaw pain upon awakening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total cost of stay
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Cervical curvature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Childhood Asthma Control Test score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acute Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Delayed Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Delayed cutaneous Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Cmax of cerivastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC of cerivastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerability of cerivastatin
Endpoint domain: Adverse events/effects
Primary endpoint: Plasma levels of IL-6, sTNF receptors, C3a, C3bc and TCC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Postoperative hemodynamics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain levels during catheterization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CVD risk factors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: degree of knee flexion contracture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Median coma recovery time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mortality with mannitol therapy
Endpoint domain: Mortality/survival
Primary endpoint: Change in incisors and first molars
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intrusion of incisors and distal-buccal cuspids of first molars
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in widths of arches in molar zone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentrations of total cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Concentrations of low-density lipoprotein cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Concentrations of triglycerides
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Success rates after 5 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical benefit rate (CR+PR+SD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of grade 3/4 adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in parental burden
Endpoint domain: Life impact
Endpoint subdomain: Societal/carer burden
Primary endpoint: Improved HRQoL in children
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Cumulative incidence of death and myocardial infarction
Endpoint domain: Mortality/survival
Primary endpoint: Rate of very late stent thrombosis
Endpoint domain: Adverse events/effects
Primary endpoint: Ongoing improvement (fractional IPSS change >2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative readmissions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Quality of Life (MSQOL-54 scores)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: E2 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: E1 to E2 ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean change in clinician‐rated MADRS score from baseline to end of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: frequency of fecal contamination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment interruption
Endpoint domain: Adverse events/effects
Primary endpoint: Subjective outcome evaluation measures
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Adequate antithrombotic therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SDQ conduct problems
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: DFT at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Chromosomal abnormality confirmation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: False positive rate
Endpoint domain: Adverse events/effects
Primary endpoint: Adherence to daily controller medication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of positive cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reaction to serotonin and methylergometrine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: intake of energy, proteins, total lipids, carbohydrates, saturated fatty acids, polyunsaturated fatty acids, cholesterol, fibre and alcohol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: PeakVO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NAPLAN score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Decline in FVC% predicted
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Prevalence of ventilator-associated pneumonia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Prostate cancer prevention
Endpoint domain: Mortality/survival
Primary endpoint: Fall injuries
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fractures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: psychomotor speed improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: cognitive inhibition improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage time spent at glucose levels below 4.0 mmol/l
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Exercise-induced hypoglycaemia
Endpoint domain: Adverse events/effects
Primary endpoint: Risk of requiring morphine
Endpoint domain: Adverse events/effects
Primary endpoint: Median time to first morphine dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak plasma bupivacaine concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative percentage of endothelial cell loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative percentage change in pachymetry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cost-effectiveness in improving function
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Quality of life as measured by the EQ‐5D visual analogue scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rates of improvement for C7 vertebra
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceptability for C2 vertebra
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle soreness at 6 weeks
Endpoint domain: Adverse events/effects
Primary endpoint: 12-month 7-day abstinence rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endometrial width
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subendometrial flow in the spiral artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median VAS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes